Matthew B Nodwell1, Hua Yang2, Helen Merkens3,4, Noeen Malik2,3, Milena Čolović3,4, Rainer E Martin5, François Bénard3,4, Paul Schaffer1,2,4, Robert Britton6. 1. Department of Chemistry, Simon Fraser University, Burnaby, British Columbia, Canada. 2. Life Sciences Division, TRIUMF, Vancouver, British Columbia, Canada. 3. Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada. 4. Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada. 5. Medicinal Chemistry, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. 6. Department of Chemistry, Simon Fraser University, Burnaby, British Columbia, Canada rbritton@sfu.ca.
Abstract
The large, neutral L-type amino acid transporters (LAT1-LAT4) are sodium-independent transporters that are widely distributed throughout the body. LAT expression levels are increased in many types of cancer, and their expression increases as cancers progress, leading to high expression levels in high-grade tumors and metastases. Because of the key role and overexpression of LAT in many types of cancer, radiolabeled LAT substrates are promising candidates for nuclear imaging of malignancies that are not well revealed by conventional radiotracers. The goal of this study was to examine the structure-activity relationships of a series of 18F-labeled amino acids that were predicted to be substrates of the LAT transport system. Methods: Using a photocatalytic radical fluorination, we prepared a series of 11 fluorinated branched-chain amino acids and evaluated them and their nonfluorinated parents in a cell-based LAT affinity assay. We radiofluorinated selected branched-chain amino acids via the same radical fluorination reaction and evaluated tumor uptake in U-87 glioma xenograft-bearing mice. Results: Structure-activity relationship trends observed in a LAT affinity assay were maintained in further in vitro studies, as well as in vivo using a U-87 xenograft model. LAT1 uptake was tolerant of fluorinated amino acid stereochemistry and chain length. PET imaging and biodistribution studies showed that the tracer (S)-5-18F-fluorohomoleucine had rapid tumor uptake, favorable in vivo kinetics, and good stability. Conclusion: By using an in vitro affinity assay, we could predict LAT-mediated cancer cell uptake in a panel of fluorinated amino acids. These predictions were consistent when applied to different cell lines and murine tumor models, and several new tracers may be suitable for further development as oncologic PET imaging agents.
The large, neutral L-type amino acid transporters (LAT1-LAT4) are sodium-independent transporters that are widely distributed throughout the body. LAT expression levels are increased in many types of cancer, and their expression increases as cancers progress, leading to high expression levels in high-grade tumors and metastases. Because of the key role and overexpression of LAT in many types of cancer, radiolabeled LAT substrates are promising candidates for nuclear imaging of malignancies that are not well revealed by conventional radiotracers. The goal of this study was to examine the structure-activity relationships of a series of 18F-labeled amino acids that were predicted to be substrates of the LAT transport system. Methods: Using a photocatalytic radical fluorination, we prepared a series of 11 fluorinated branched-chain amino acids and evaluated them and their nonfluorinated parents in a cell-based LAT affinity assay. We radiofluorinated selected branched-chain amino acids via the same radical fluorination reaction and evaluated tumor uptake in U-87 glioma xenograft-bearing mice. Results: Structure-activity relationship trends observed in a LAT affinity assay were maintained in further in vitro studies, as well as in vivo using a U-87 xenograft model. LAT1 uptake was tolerant of fluorinated amino acid stereochemistry and chain length. PET imaging and biodistribution studies showed that the tracer (S)-5-18F-fluorohomoleucine had rapid tumor uptake, favorable in vivo kinetics, and good stability. Conclusion: By using an in vitro affinity assay, we could predict LAT-mediated cancer cell uptake in a panel of fluorinated amino acids. These predictions were consistent when applied to different cell lines and murinetumor models, and several new tracers may be suitable for further development as oncologic PET imaging agents.
Authors: Thomas R Belliotti; Thomas Capiris; I Victor Ekhato; Jack J Kinsora; Mark J Field; Thomas G Heffner; Leonard T Meltzer; Jacob B Schwarz; Charles P Taylor; Andrew J Thorpe; Mark G Vartanian; Lawrence D Wise; Ti Zhi-Su; Mark L Weber; David J Wustrow Journal: J Med Chem Date: 2005-04-07 Impact factor: 7.446
Authors: T Inoue; T Shibasaki; N Oriuchi; K Aoyagi; K Tomiyoshi; S Amano; M Mikuni; I Ida; J Aoki; K Endo Journal: J Nucl Med Date: 1999-03 Impact factor: 10.057
Authors: L M Roberts; D S Black; C Raman; K Woodford; M Zhou; J E Haggerty; A T Yan; S E Cwirla; K K Grindstaff Journal: Neuroscience Date: 2008-06-13 Impact factor: 3.590
Authors: George Crișan; Nastasia Sanda Moldovean-Cioroianu; Diana-Gabriela Timaru; Gabriel Andrieș; Călin Căinap; Vasile Chiș Journal: Int J Mol Sci Date: 2022-04-30 Impact factor: 6.208